These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1361352)

  • 1. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
    Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
    Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
    J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication.
    Bollinger RC; Quinn TC; Liu AY; Stanhope PE; Hammond SA; Viveen R; Clements ML; Siliciano RF
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1067-77. PubMed ID: 7906131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine.
    Stanhope PE; Clements ML; Siliciano RF
    J Infect Dis; 1993 Jul; 168(1):92-100. PubMed ID: 8099941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines.
    Miskovsky EP; Liu AY; Pavlat W; Viveen R; Stanhope PE; Finzi D; Fox WM; Hruban RH; Podack ER; Siliciano RF
    J Immunol; 1994 Sep; 153(6):2787-99. PubMed ID: 7915742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
    McElrath MJ; Corey L; Greenberg PD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
    Becker Y
    Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
    Achour A; Moukrim Z; Picard O; Bizzini B; Burny A; Zagury D
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):395-400. PubMed ID: 7580833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism.
    Liu AY; Miskovsky EP; Stanhope PE; Siliciano RF
    J Immunol; 1992 Jun; 148(12):3789-98. PubMed ID: 1351088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
    J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.